Drugs / Levodopa
Levodopa
also known as
CVT-301 · L-DOPA · DUODOPA · Levodopa Cyclops · LIP · melevodopa/carbidopa · Sinemet · Sirio · +1 more
targets GPR143 via activation
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed Parkinson disease 4 milestones | |||||
| Rejected (CRL) | US (FDA) | Vadova | Parkinson disease | 2008-01-30 | “received a non-approvable letter from the U.S. Food and Drug Administration (FDA) concerning its new drug application (NDA) and subsequent submissions for Vadova(R)...” amneal.com ↗ |
| Filed | US (FDA) | Vadova | Parkinson disease | 2007-01-18 | “filed an amendment to its new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for its Vadova(TM) (carbidopa/levodopa) tablets.” amneal.com ↗ “the triple tablet combining entacapone with levodopa and carbidopa were filed by Orion Pharma with the US regulatory authority FDA in late August” orionpharma.com ↗ “New Drug Applications for Triple Combination Tablet for Parkinson's under review in the US and the EU” orionpharma.com ↗ |
| Rejected (CRL) | US (FDA) | Vadova | Parkinson disease | 2006-03-07 | “received a non-approvable letter from the U.S. Food and Drug Administration (FDA) concerning its new drug application for Vadova(R) (carbidopa/levodopa) tablets.” amneal.com ↗ |
| Filed | EU (EMA) | — | Parkinson disease | — | “New Drug Applications for Triple Combination Tablet for Parkinson's under review in the US and the EU” orionpharma.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Approved | EU (EMA) | Stalevo | — | 2003-10-17 | europa.eu ↗ |
| Label expansion | US (FDA) | DOPAR | — | 1975-02-27 | fda.gov ↗ |
| Approved | US (FDA) | LARODOPA | — | 1970-06-04 | fda.gov ↗ |
Trials 120 · started per year
today
US approved 1970
EU approved 2003
1
1
3
1
3
5
10
8
1
2
5
3
3
5
3
7
10
8
6
2
5
6
5
4
6
2
3
2
1969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05471609 | Jun → Aug 2025 | — | University of Minnesota | Completed | No outcome recorded |
| Phase 0 | NCT05132660 | Jul 2022 → Dec 2027 expected | diabetic retinopathy | VA Office of Research and Development | Enrolling by invitation | No outcome recorded |
| Phase 134 trials · 2 met primary | ||||||
| Phase 1 | NCT07442591 | Mar → Apr 2026 | — | Shanghai WD Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06037590 | Sep → Oct 2023 | Parkinson disease | PureIMS B.V. | Completed | Met primary |
| Phase 1 | NCT05708274 | Jan 2023 → Oct 2025 | spinal cord injury | Bronx VA Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT05250141 | Feb 2022 | — | Laboratorios Andromaco S.A. | Completed | No outcome recorded |
| Phase 1 | NCT05128175 | Oct 2021 → Jan 2022 | Parkinson disease | Shanghai WD Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04591535 | Sep 2020 → Mar 2021 | Parkinson disease | Hong Kong WD Pharmaceutical Co., Limited | Unknown | No outcome recorded |
| Phase 1 | NCT04553978 | Sep 2020 → Mar 2021 | Parkinson disease | Hong Kong WD Pharmaceutical Co., Limited | Unknown | No outcome recorded |
| Phase 1 | NCT04513340 | Aug → Sep 2020 | Parkinson disease | Hong Kong WD Pharmaceutical Co., Limited | Unknown | No outcome recorded |
| Phase 1 | NCT03887884 | Mar → Jun 2019 | Parkinson disease | Acorda Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03496870 | Feb → Jul 2018 | Parkinson disease | Neurocrine Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT03205956 | Oct 2017 → Oct 2019 | Parkinson disease | Kevin J. Black, MD | Completed | No outcome recorded |
| Phase 1 | NCT03140956 | Apr → Jul 2017 | Parkinson disease | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03055936 | Feb → Jun 2017 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02812394 | Jun → Aug 2016 | Parkinson disease | Acorda Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02807675 | Jun → Nov 2016 | Parkinson disease | Acorda Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02706977 | Jan 2016 → Aug 2019 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT02633007 | Dec 2015 → Mar 2016 | asthma | Acorda Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02633839 | Dec 2015 → Apr 2016 | — | Acorda Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02554734 | Aug → Nov 2015 | Parkinson disease | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02448914 | May → Jul 2015 | Parkinson disease | LobSor Pharmaceuticals AB | Completed | Met primary |
| Phase 1 | NCT02486432 | Apr 2015 | Parkinson disease | NeuroDerm Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02312232 | Nov 2014 → Feb 2015 | Parkinson disease | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02096601 | Aug 2014 → Mar 2015 | Parkinson disease | NeuroDerm Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01484990 | Apr → Sep 2010 | Parkinson disease | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT01519284 | Nov 2009 → Feb 2010 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02169895 | Sep → Nov 2008 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT00693862 | Dec 2006 → Apr 2008 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03097211 | Jul → Oct 2006 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT03094156 | Apr → Jul 2006 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT00634556 | Feb 2006 → Oct 2010 | Tourette syndrome | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02778594 | Sep → Nov 2005 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02774564 | Sep → Nov 2005 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT03091543 | May → Jul 2004 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02763839 | Apr → Jul 2001 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT06831500 | Jul 2025 → Nov 2026 expected | Parkinson disease, multiple system atrophy, parkinsonian type, orthostatic hypotension | Julien Bally | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02696512 | Mar 2016 → Mar 2017 | brain injury | International Brain Research Foundation | Unknown | No outcome recorded |
| Phase 1/2 | NCT01026428 | Sep 2009 → Jul 2010 | Parkinson disease | Newron Pharmaceuticals SPA | Completed | No outcome recorded |
| Phase 1/2 | NCT00491998 | Nov 2006 → Nov 2007 | Parkinson disease | Vernalis (R&D) Ltd | Completed | No outcome recorded |
| Phase 1/2 | NCT00239564 | Oct 2005 → Dec 2007 | Parkinson disease | Impax Laboratories, LLC | Completed | No outcome recorded |
| Phase 225 trials · 1 met primary | ||||||
| Phase 2 | NCT06626152 | Aug 2024 → May 2026 overdue | major depressive disorder | University of British Columbia | Recruiting | No outcome recorded |
| Phase 2 | NCT07444892 | Apr 2022 → Nov 2025 | diabetic retinopathy | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT05036473 | Nov 2021 → Dec 2022 | Parkinson disease | Shanghai WD Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04778176 | Jun 2021 → Jul 2022 | Parkinson disease | SynAgile Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02873351 | Sep 2019 → Dec 2020 | age-related macular degeneration | Snyder, Robert W., M.D., Ph.D., P.C. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03197493 | Aug 2017 → Jul 2020 | age-related macular degeneration | Snyder, Robert W., M.D., Ph.D., P.C. | Completed | No outcome recorded |
| Phase 2 | NCT03022318 | May 2017 → Dec 2019 | age-related macular degeneration | Snyder, Robert W., M.D., Ph.D., P.C. | Completed | No outcome recorded |
| Phase 2 | NCT02577523 | Dec 2015 → Dec 2016 | Parkinson disease | NeuroDerm Ltd. | Completed | Met primary |
| Phase 2 | NCT02271503 | Nov 2015 → Aug 2016 | Parkinson disease | Impax Laboratories, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02080819 | Feb 2014 → Jan 2017 | cocaine dependence | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 2 | NCT01777555 | Apr 2013 → Jan 2014 | Parkinson disease | Acorda Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01663935 | Oct 2012 → Apr 2018 | albinism, oculocutaneous albinism | University of Wisconsin, Madison | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00947037 | Aug 2012 | Parkinson disease | Intec Pharma Ltd. | Withdrawn | No outcome recorded |
| Phase 2 | NCT01617135 | May → Nov 2012 | Parkinson disease | Acorda Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01515410 | Jan → Sep 2012 | Parkinson disease | Depomed | Completed | No outcome recorded |
| Phase 2 | NCT01291537 | Nov 2011 → Mar 2016 | Parkinson disease | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01568047 | Feb → Jun 2010 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 2 | NCT00918177 | Jul 2009 → Oct 2012 | Parkinson disease | Intec Pharma Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00713583 | Jan 2008 → Dec 2011 | cocaine dependence | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2 | NCT00218023 | Mar 2006 → Apr 2012 | cocaine abuse | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2 | NCT00253084 | Nov 2005 → Dec 2007 | Parkinson disease | Impax Laboratories, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00096720 | Feb 2004 → May 2007 | Parkinson disease | Institute for Neurodegenerative Disorders | Completed | No outcome recorded |
| Phase 2 | NCT00076674 | Jan 2004 → Oct 2005 | Parkinson disease, drug-induced dyskinesia | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT00013624 | Mar 2001 → Mar 2005 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT00218075 | Mar 2000 → Oct 2007 | cocaine abuse | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2/33 trials · 1 missed | ||||||
| Phase 2/3 | NCT05487300 | May 2022 → May 2023 | Parkinson disease, orthostatic hypotension | University of Utah | Completed | No outcome recorded |
| Phase 2/3 | NCT01468012 | Jul 2014 | cocaine dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT01281475 | Jan 2011 → Jul 2015 | Angelman syndrome | Wen-Hann Tan | Completed | Missed primary |
| Phase 314 trials · 2 met primary | ||||||
| Phase 3 | NCT04379050 | Jun 2020 → Apr 2026 | Parkinson disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03462043 | Apr → Nov 2018 | Parkinson disease | NeuroDerm Ltd. | Withdrawn | No outcome recorded |
| Phase 3 | NCT02615873 | Jul 2016 → Dec 2019 | Parkinson disease | Intec Pharma Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT02605434 | Mar 2016 → Jul 2019 | Parkinson disease | Intec Pharma Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT02352363 | Mar 2015 → May 2017 | Parkinson disease | Acorda Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT02242487 | Mar 2015 → May 2018 | Parkinson disease | Acorda Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT02240030 | Nov 2014 → Dec 2016 | Parkinson disease | Acorda Therapeutics | Completed | Met primary |
| Phase 3 | NCT02073773 | Jan 2014 → Nov 2015 | ischemic stroke | Singapore General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01736176 | Mar 2013 → Mar 2015 | Parkinson disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT00134966 | Aug 2005 → Sep 2007 | Parkinson disease | Novartis | Completed | Met primary |
| Phase 3 | NCT00139880 | Jun → Aug 2005 | Parkinson disease | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00144209 | Feb 2003 → Feb 2005 | restless legs syndrome | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00625547 | Jan 2003 → Dec 2004 | restless legs syndrome | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00004733 | Jan 1998 → Feb 2004 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 424 trials · 2 met primary · 1 missed | ||||||
| Phase 4 | NCT06765668 | Feb → Nov 2025 overdue | Parkinson disease | Impax Laboratories, LLC | Recruiting | No outcome recorded |
| Phase 4 | NCT06075771 | Nov 2023 → Jan 2027 expected | atypical depressive disorder, depressive disorder | Emory University | Recruiting | No outcome recorded |
| Phase 4 | NCT06236230 | Nov 2023 → Jun 2024 | Parkinson disease | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 4 | NCT06013956 | Aug 2023 → Jun 2028 expected | Parkinson disease | David Escobar | Recruiting | No outcome recorded |
| Phase 4 | NCT04742348 | Feb → Aug 2023 | alcohol-related disorders | University of Washington | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT06234995 | Aug 2021 → Sep 2027 expected | Parkinson disease | Emory University | Recruiting | No outcome recorded |
| Phase 4 | NCT04723147 | Jan 2021 → Oct 2023 | atypical depressive disorder, depressive disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT04821830 | Feb 2020 → Apr 2024 | Parkinson disease | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT03761030 | Jan 2019 → Sep 2021 | dysthymic disorder, major depressive disorder | New York State Psychiatric Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03111485 | May 2017 → Oct 2022 | Parkinson disease, obstructive sleep apnea syndrome | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 4 | NCT02744391 | Aug 2016 → Sep 2018 | dysthymic disorder, major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT02769793 | Jun 2015 → Aug 2018 | Parkinson disease | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01683253 | Nov 2012 → Dec 2014 | impulse control disorder | Sandoz | Completed | No outcome recorded |
| Phase 4 | NCT01327261 | Aug → Oct 2009 | — | University of Buenos Aires | Completed | Met primary |
| Phase 4 | NCT00914134 | Apr 2009 → Jan 2011 | Parkinson disease | University of Helsinki | Completed | No outcome recorded |
| Phase 4 | NCT00272688 | Jan 2006 → May 2009 | Parkinson disease | University Hospital, Akershus | Completed | No outcome recorded |
| Phase 4 | NCT00306124 | Jan 2006 → Mar 2008 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | University Hospital Muenster | Unknown | No outcome recorded |
| Phase 4 | NCT00126087 | Jul 2005 → Dec 2007 | stroke disorder | University Hospital Muenster | Terminated | Met primary Stop: Enrollment |
| Phase 4 | NCT00102869 | Jan 2005 → Feb 2007 | aphasia, stroke disorder | University Hospital Muenster | Completed | Missed primary |
| Phase 4 | NCT00111371 | Jan 2005 → Oct 2015 | dyslexia | University Hospital Muenster | Unknown | No outcome recorded |
| Phase 4 | NCT00174239 | Jul 2004 → Sep 2005 | Parkinson disease | Pfizer | Terminated | No outcome recorded |
| Phase 4 | NCT00102284 | Mar 2004 → Apr 2005 | — | University Hospital Muenster | Terminated | No outcome recorded |
| Phase 4 | NCT00103805 | Mar 2003 → Aug 2005 | — | University Hospital Muenster | Completed | No outcome recorded |
| Phase 4 | NCT00812760 | Oct 2001 → Oct 2003 | retinal disorder | Medical University of Vienna | Completed | No outcome recorded |
| Phase not applicable13 trials | ||||||
| — | NCT07647913 | Sep 2026 → Sep 2027 expected | Parkinson disease | McMaster University | Not yet recruiting | No outcome recorded |
| — | NCT06365515 | May 2024 → Dec 2025 | menstrual disorder | University Hospital Tuebingen | Unknown | No outcome recorded |
| — | NCT03665493 | Sep 2020 → Jan 2023 | Parkinson disease | Giovanni Mirabella | Completed | No outcome recorded |
| — | NCT05901350 | Jun 2019 → Jun 2022 | Parkinson disease, vision disorder | Qilu Hospital of Shandong University | Completed | No outcome recorded |
| — | NCT06275633 | Mar 2019 → Dec 2021 | Parkinson disease, cognitive impairment with or without cerebellar ataxia, depressive disorder | University Hospital Bispebjerg and Frederiksberg | Completed | No outcome recorded |
| — | NCT02785978 | Jun 2016 → Jun 2017 | Parkinson disease | Institut de Myologie, France | Completed | No outcome recorded |
| — | NCT01937169 | Jan 2014 → Jan 2016 | restless legs syndrome | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| — | NCT03235037 | Nov 2013 → Feb 2019 | Angelman syndrome | Bennett Lavenstein | Completed | No outcome recorded |
| — | NCT01577992 | Dec 2011 → Jun 2013 | multiple system atrophy | University Hospital, Toulouse | Completed | No outcome recorded |
| — | NCT01218425 | Nov 2010 → Jun 2012 | — | Maastricht University Medical Center | Completed | No outcome recorded |
| — | NCT00941265 | Feb 2007 → Aug 2009 | aphasia | University Hospital, Geneva | Completed | No outcome recorded |
| — | NCT00129181 | Jan 2005 → Dec 2006 | Parkinson disease | Institute for Neurodegenerative Disorders | Completed | No outcome recorded |
| — | NCT01044992 | May 2002 → May 2005 | multiple system atrophy | University Hospital, Toulouse | Completed | No outcome recorded |
| Comparator or background therapy64 trials | ||||||
| Phase 0 | NCT03333369 Comparator | May 2014 → Aug 2015 | schizotypal personality disorder | University of Zurich | Completed | No outcome recorded |
| Phase 1 | NCT04052776 Comparator | Sep 2020 → Oct 2023 | spinal cord injury | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 1 | NCT03929068 Comparator | May 2019 → Jul 2022 | amyotrophic lateral sclerosis | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02116465 Comparator | Mar 2014 | — | Desitin Arzneimittel GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01486628 Comparator | Apr → Nov 2012 | Parkinson disease | NeuroDerm Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00845000 Background | Apr 2009 → Apr 2010 | Parkinson disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00505843 Background | May 2007 → Feb 2008 | Parkinson disease | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 1 | NCT02763852 Background | Apr → Jul 2001 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1/2 | NCT07246278 Comparator | Nov 2025 → Nov 2026 expected | Parkinson disease | Tanta University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03119636 Background | May 2017 → Nov 2018 | Parkinson disease | Chinese Academy of Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT01484184 Comparator | Jul 2013 → Aug 2015 | spinal cord injury | Nordic Life Science Pipeline Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00914602 Comparator | May 2009 → Jan 2010 | Parkinson disease | XenoPort, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT07001150 Comparator | May 2025 → May 2026 overdue | Parkinson disease | Tanta University | Recruiting | No outcome recorded |
| Phase 2 | NCT06612593 Background | Oct 2024 → Oct 2025 overdue | Parkinson disease | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06614153 Comparator | May 2023 → Jan 2024 | Parkinson disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05781711 Background | Jan 2023 → Jan 2025 | Parkinson disease | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT03000569 Background | Nov 2016 → Sep 2017 | Parkinson disease | Biogen | Completed | No outcome recorded |
| Phase 2 | NCT02764125 Background | Apr 2016 → Mar 2018 | Parkinson disease | Orion Corporation, Orion Pharma | Completed | Met primary |
| Phase 2 | NCT02680977 Comparator | Feb → May 2016 | Parkinson disease | ASST Gaetano Pini-CTO | Completed | No outcome recorded |
| Phase 2 | NCT02641054 Background | Feb 2016 → Jun 2017 | Parkinson disease | CleveXel Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02763137 Comparator | Jul 2014 → Oct 2015 | Parkinson disease | IRCCS San Raffaele Roma | Completed | No outcome recorded |
| Phase 2 | NCT01479127 Background | Oct 2011 → Jul 2012 | Parkinson disease | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01176435 Comparator | Sep 2010 → Dec 2014 | albinism | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT01568034 Background | Apr 2009 → Feb 2010 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 2 | NCT00789672 Comparator | Jan → Sep 2009 | amblyopia | Jaeb Center for Health Research | Completed | No outcome recorded |
| Phase 2 | NCT00558337 Comparator | Nov 2007 → Dec 2008 | Parkinson disease | Osmotica Pharmaceutical US LLC | Completed | No outcome recorded |
| Phase 2 | NCT03103399 Background | Sep 2006 → Sep 2007 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 2 | NCT00108667 Background | Apr 2005 → Feb 2006 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT00089622 Background | Aug 2004 → Mar 2007 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT00086294 Background | Jun 2004 → Nov 2007 | Parkinson disease, drug-induced dyskinesia | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT00040209 Background | Jun 2002 → Jul 2005 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT00009048 Background | Jan 2001 → Dec 2003 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT00006337 Background | Oct 2000 → Jan 2002 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT00006077 Background | Aug 2000 → Jul 2003 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT01351168 Comparator | — | Parkinson disease | Rush University Medical Center | Withdrawn | No outcome recorded Stop: Business |
| Phase 2/3 | NCT07229664 Comparator | Nov 2025 → Nov 2026 expected | Parkinson disease | Tanta University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07229651 Comparator | Nov 2025 → Nov 2026 expected | Parkinson disease | Tanta University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06785298 Comparator | Dec 2024 → Dec 2026 expected | Parkinson disease | Tanta University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06113640 Comparator | Nov 2023 → Aug 2026 | Parkinson disease | Mostafa Bahaa | Completed | No outcome recorded |
| Phase 2/3 | NCT05001217 Background | Jan 2022 → Dec 2023 | Parkinson disease | Hong Kong Baptist University | Completed | No outcome recorded |
| Phase 2/3 | NCT02601586 Comparator | Sep 2016 → Nov 2020 | Parkinson disease | University Hospital, Toulouse | Completed | Missed primary |
| Phase 2/3 | NCT01283594 Background | Mar 2011 → Oct 2012 | Parkinson disease | Biotie Therapies Inc. | Completed | Met primary |
| Phase 2/3 | NCT01429077 Comparator | Oct 2007 → Mar 2012 | aphasia, stroke disorder | Shirley Ryan AbilityLab | Completed | No outcome recorded |
| Phase 3 | NCT03735901 Comparator | Jun 2019 → Aug 2024 overdue | stroke disorder | University Hospital, Basel, Switzerland | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01568073 Background | Mar 2011 → Nov 2013 | Parkinson disease | Bial - Portela C S.A. | Completed | Met primary |
| Phase 3 | NCT01227655 Background | Mar 2011 → Jul 2012 | Parkinson disease | Bial - Portela C S.A. | Completed | Met primary |
| Phase 3 | NCT01190813 Comparator | Sep 2010 → Jan 2014 | amblyopia | Jaeb Center for Health Research | Completed | No outcome recorded |
| Phase 3 | NCT00357994 Comparator | Jan 2009 → Oct 2011 | Parkinson disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT00406588 Background | Mar 2007 → Apr 2008 | Parkinson disease | Solvay Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00099268 Comparator | Sep 2004 → Nov 2008 | Parkinson disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT06316232 Comparator | Oct 2023 → Dec 2026 expected | Parkinson disease, primary progressive freezing gait | IRCCS Istituto delle Scienze Neurologiche di Bologna | Recruiting | No outcome recorded |
| Phase 4 | NCT02560389 Comparator | Mar 2016 → May 2018 | post-traumatic stress disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 4 | NCT02513485 Comparator | Oct 2015 → Feb 2020 | major depressive disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02346630 Comparator | Mar 2015 → Mar 2017 | stroke disorder | Ross D. Zafonte, MD | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT01951105 Comparator | Feb 2015 → Sep 2017 | subacute bursitis | Northwestern University | Completed | No outcome recorded |
| Phase 4 | NCT00642356 Background | Mar 2008 → May 2009 | Parkinson disease | Novartis | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00391898 Background | Oct 2006 → Jun 2008 | Parkinson disease | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00399477 Background | Oct 2006 → Jul 2007 | Parkinson disease | Teva Neuroscience, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00143026 Background | Jul 2005 → Jun 2006 | Parkinson disease | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00153972 Comparator | Feb 2005 → Sep 2008 | Parkinson disease | Technical University Dresden | Completed | No outcome recorded |
| Phase 4 | NCT00219284 Background | Jan 2005 → Jul 2008 | Parkinson disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| — | NCT04590612 Comparator | Jan 2021 → Jan 2022 | Parkinson disease, depressive disorder | Western University, Canada | Unknown | No outcome recorded |
| — | NCT04054960 Comparator | Sep 2019 → Sep 2021 | Parkinson disease | Western University, Canada | Unknown | No outcome recorded |
| — | NCT01470859 Comparator | Dec 2011 → Aug 2014 | Parkinson disease | Huashan Hospital | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 36
| Date | Issuer | Release |
|---|---|---|
| 2026-08-28 | Zambon SpA | Regulatory Zambon announces European Commission approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations zambon.com ↗
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. |
| 2026-06-29 | Impax Laboratories, LLC | Regulatory Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations amneal.com ↗ |
| 2026-06-05 | Impax Laboratories, LLC | Results Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease amneal.com ↗
After patients switched from prior therapies, treatment with CREXONT delivered meaningful increases in “Good On” time, reductions in “Off” time, and improved motor symptom control. |
| 2025-12-05 | Impax Laboratories, LLC | Results Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease amneal.com ↗
CREXONT delivered substantial “Off” time reductions, improved motor symptom control and provided a longer duration of benefit with each dose |
| 2025-09-02 | PureIMS B.V. | Results An In Vitro–In Vivo Comparison of Two Levodopa Dry Powder Products for Inhalation: A Randomized Trial Comparing Inbrija and Levodopa Cyclops pureims.com ↗
Despite this in vitro difference, the pharmacokinetic profiles of Inbrija 84 mg and Levodopa Cyclops 90 mg were similar, with no differences in Cmax, Tmax, and AUC, showing bioequivalence between the two products. |
| 2025-04-07 | Impax Laboratories, LLC | Results Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease amneal.com ↗
Analysis of RISE-PD presented at AAN 2025 showed CREXONT treatment significantly improved patients’ Parkinson’s Disease Sleep Scale-2 (PDSS-2) total and sub-scale scores |
| 2024-09-18 | PureIMS B.V. | Results International Congress of Parkinson’s Disease and Movement Disorders 2024 – poster on Levodopa Cyclops® pureims.com ↗
Levodopa absorption from Cyclops® is comparable to Inbrija®, thereby, fulfilling the bioequivalence criteria. |
| 2024-08-07 | Impax Laboratories, LLC | Regulatory Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules amneal.com ↗
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved CREXONT ® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease (PD). |
| 2024-01-18 | PureIMS B.V. | Results PureIMS gears up for abbreviated registration of Levodopa Cyclops® against OFF episodes in Parkinson’s disease with the successful completion of a comparative pharmacokinetic study pureims.com ↗
The study results show rapid pulmonary absorption of levodopa in absence of safety and tolerability issues. |
| 2023-08-24 | Impax Laboratories, LLC | Results JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease amneal.com ↗
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that JAMA Neurology has published results from the RISE-PD clinical study assessing the efficacy and safety of IPX203 versus optimized immediate-release carbidopa/levodopa (IR CD/LD) for the treatment of Parkinson’s disease (PD). |
| 2023-04-06 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from the USFDA for Carbidopa and Levodopa Tablets USP, 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg zyduslife.com ↗
Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Carbidopa and Levodopa Tablets USP, 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg (USRLD: Sinemet Tablets, 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg). |
| 2022-03-31 | AbbVie | Results Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022 abbvie.com ↗
The results show that levodopa treatment occurs more consistently than dopamine agonist treatment, as patients prescribed dopamine agonists had relatively high treatment modification and discontinuation rates and low medication adherence. |
| 2021-10-28 | AbbVie | Results AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease abbvie.com ↗
The increase in "On" time at week 12 was 2.72 hours for ABBV-951 versus 0.97 hours for oral levodopa/carbidopa (LD/CD) (p= 0.0083). |
| 2020-09-17 | LobSor Pharmaceuticals AB | Regulatory Lobsor Pharmaceuticals receive approval for Lecigon in Germany, the Netherlands, Belgium, Austria, Slovenia and Romania lobsor.com ↗
Lobsor Pharmaceuticals receive approval for Lecigon in Germany, the Netherlands, Belgium, Austria, Slovenia and Romania |
| 2019-10-01 | LobSor Pharmaceuticals AB | Regulatory Lobsor Pharmaceuticals receive approval for Lecigon® in Denmark, Finland and Norway lobsor.com ↗
Lobsor Pharmaceuticals AB today announced that Lecigon has been approved, and that the Swedish Medical Products Agency (MPA) has confirmed End of Procedure according to the European Mutual Recognition Procedure (MRP) including Denmark, Finland and Norway. |
| 2019-06-01 | Alembic Pharmaceuticals Ltd. | Regulatory 5th June, 2019, Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited today announced that the Company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Carbidopa and Levodopa Extended-Release Tablets USP, 2.5 mg/100 mg and 50 mg/200 mg. |
| 2016-08-09 | Impax Laboratories, LLC | Results Impax Reports Second Quarter 2016 Financial Results amneal.com ↗
The results of the interim analysis showed that IPX203 exhibited a statistically significant improvement in the reduction of "off" time compared to both immediate-release CD-LD and Rytary. |
| 2015-11-25 | Impax Laboratories, LLC | Regulatory Impax Receives European Commission Marketing Authorization for NUMIENT™ (Levodopa and Carbidopa) Modified-Release Capsules for the Symptomatic Treatment of Adult Patients with Parkinson's Disease amneal.com ↗
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the European Commission (EC) has granted marketing authorization for NUMIENT (Levodopa and Carbidopa), a modified-release oral capsule formulation for the symptomatic treatment of adult patients with Parkinson's disease. |
| 2015-09-25 | Impax Laboratories, LLC | Regulatory Impax Receives Positive CHMP Opinion for NUMIENT™ (Levodopa and Carbidopa) Modified-Release Capsules for the Symptomatic Treatment of Adult Patients with Parkinson's disease amneal.com ↗ |
| 2015-01-12 | AbbVie | Regulatory AbbVie Announces U.S. FDA Approval of DUOPA™ (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson's Disease abbvie.com ↗
The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE: ABBV) DUOPA™ (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson's disease. |
| 2015-01-08 | Impax Laboratories, LLC | Regulatory Impax Pharmaceuticals Announce FDA Approval of RYTARY™ (Carbidopa and Levodopa) Extended-Release Capsules for the Treatment of Parkinson's disease amneal.com ↗
Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that the U.S. Food and Drug Administration ( FDA ) approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication. |
| 2014-04-11 | Impax Laboratories, LLC | Regulatory Impax Pharmaceuticals Resubmits New Drug Application for RYTARY™ (Carbidopa and Levodopa) Extended-Release Capsules (IPX066) amneal.com ↗
Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced today the resubmission of Impax's New Drug Application (NDA) for RYTARY (IPX066) to the U.S. Food and Drug Administration ( FDA ). |
| 2013-03-19 | Impax Laboratories, LLC | Results Impax Pharmaceuticals Announces Presentation of RYTARYTM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extension Data at the American Academy of Neurology 2013 Annual Meeting amneal.com ↗
During this clinical trial, the total daily IPX066 levodopa dose was approximately double that of the levodopa IR dose received. |
| 2013-01-21 | Impax Laboratories, LLC | Regulatory FDA Issues Complete Response Letter for RYTARY™ (Carbidopa and Levodopa) Extended-Release Capsules (IPX066) New Drug Application amneal.com ↗ |
| 2012-07-16 | Addex Pharma S.A. | Results Addex Announces the Publication of Positive Data on the Efficacy of mGluR4 Positive Allosteric Modulator in Parkinson’s Disease Pre-Clinical Models addextherapeutics.com ↗
More importantly, the combination of ADX88178 (3, 10 and 30 mg/kg, p.o.) with a low dose of L-DOPA enabled a robust, dose-dependent reversal of the forelimb akinesia deficit induced to a bilateral 6-OHDA lesion of the striatum in rats. |
| 2011-08-15 | GlaxoSmithKline | Results GSK and Impax announce positive topline results of ASCEND-PD Phase III study of IPX066 in Advanced Parkinson’s disease gsk.com ↗ |
| 2011-03-14 | GlaxoSmithKline | Results GSK announces positive topline results of Phase lll study of IPX066 in advanced Parkinson’s disease gsk.com ↗
Issued: London UK & Philadelphia, US GlaxoSmithKline (GSK) today announced positive, top-line results of the ADVANCE-Parkinson’s Disease (PD) Phase III clinical study, conducted by Impax Pharmaceuticals, of IPX066 versus immediate-release (IR) carbidopa-levodopa (CD-LD) in advanced PD patients experiencing motor fluctuations. |
| 2008-11-05 | Sun Pharmaceutical Industries, Inc. | Regulatory Sun Pharmaceutical announces USFDA approval to market generic Sinemet® tablets sunpharma.com ↗ |
| 2008-11-03 | Orion Corporation, Orion Pharma | Regulatory Orion comments on ANDA filed by Wockhardt Limited for a generic version of Orion's proprietary drug Stalevo® in the United States orionpharma.com ↗
At this point, the ANDA review process is just beginning and the realisation of generic competition is neither certain nor imminent. |
| 2008-01-30 | Impax Laboratories, LLC | Regulatory IMPAX Receives FDA Non-Approvable Letter for Vadova(R); Company Considering Options amneal.com ↗
IMPAX Laboratories, Inc. (OTC:IPXL) today announced that it has received a non-approvable letter from the U.S. Food and Drug Administration (FDA) concerning its new drug application (NDA) and subsequent submissions for Vadova(R) (carbidopa/levodopa extended release) tablets. |
| 2007-08-25 | Sun Pharmaceutical Industries, Inc. | Regulatory Sun Pharma announces USFDA approval for Sinemet CR, an extended release version of Carbidopa with Levodopa sunpharma.com ↗
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted approval for the company’s Abbreviated New Drug Applic ation (ANDA) for generic Sinemet CR, an extended release version of carbidopa with levodopa. |
| 2007-06-08 | Impax Laboratories, LLC | Results IMPAX Presents at Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders amneal.com ↗
The combined immediate- and extended-release preparation may offer benefits in treating Parkinson's Disease (PD) patients with motor fluctuations. |
| 2007-01-18 | Impax Laboratories, LLC | Regulatory IMPAX Files Amendment to Vadova(TM) NDA amneal.com ↗
IMPAX Laboratories, Inc. (OTC:IPXL) today announced that it has filed an amendment to its new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for its Vadova(TM) (carbidopa/levodopa) tablets. |
| 2006-03-07 | Impax Laboratories, LLC | Regulatory IMPAX Receives FDA Non-Approvable Letter for Vadova; Company to Request Meeting With FDA amneal.com ↗
IMPAX Laboratories, Inc. (OTC:IPXL) today announced that it has received a non-approvable letter from the U.S. Food and Drug Administration (FDA) concerning its new drug application for Vadova(R) (carbidopa/levodopa) tablets. |
| 2004-10-04 | Orion Corporation, Orion Pharma | Results Selegiline slows down the progression of Parkinson's disease symptoms orionpharma.com ↗
The better symptom control was achieved with lower daily dose of levodopa in the selegiline+levodopa group compared to patients receiving levodopa alone. |
| 2002-09-23 | Orion Corporation, Orion Pharma | Regulatory Combination tablet for Parkinson's disease now filed also in Europe by Orion Pharma orionpharma.com ↗
The new drug application by Orion Pharma for a triple combination tablet for Parkinson's disease is under review by the European Agency for the Evaluation of Medicinal Products (EMEA), the pharmaceutical regulatory authority for the EU countries. |
All press releases naming this drug 60 releases
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 185 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | levodopa | “Those assigned to L-DOPA will begin taking 37.5mg carbidopa/150 mg levodopa once daily (with placebo twice daily) for one week, then increase to 75mg carbidopa/300mg levodopa...” NCT03761030 ↗179“The goal of this multicentric prospective randomized controlled clinical and economic study is to investigate the effectiveness and cost-utility of long-term continuous...” NCT01291537 ↗ “To test whether Parcopa, a new Orally Disintegrating Tablet of Carbidopa-Levodopa, has a faster onset of action, changes in the UPDRS Motor Exam score at intervals after a...” NCT00139880 ↗ “first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed...” NCT03665493 ↗ “Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12,...” NCT02696512 ↗ “The drug Levodopa (L-DOPA), which can replace missing dopamine in the brain, has been used to treat to treat Parkinson's disease for many decades, and it might also affect...” NCT06626152 ↗ “CREXONT ER capsules will contain Carbidopa (CD)/Levodopa (LD) 35.0 milligrams (mg)/140 mg and/or CD/LD 52.5 mg/210.0 mg and/or CD/LD 70.0 mg/280 mg and/or CD/LD 87.5 mg/350 mg.” NCT06765668 ↗ “Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.” NCT02633839 ↗ “Patients received 3 doses of levodopa (100mg of levodopa plus 25mg of carbidopa) or placebo before 1 session of procedural motor learning.” PMID 18760148 ↗ Sep 2008 “Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients” NCT02763137 ↗ “1 capsule of Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) in an open label manner, concomitantly with BIA 6-512/Placebo.” NCT03091543 ↗ |
| Known as | CVT-301 | “A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets” NCT02812394 ↗8“Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function” PMID 30663606 ↗ Feb 2019 “CVT-301 levodopa (l-dopa)” NCT02807675 ↗ |
| Known as | DUODOPA | “The goal of this multicentric prospective randomized controlled clinical and economic study is to investigate the effectiveness and cost-utility of long-term continuous...” NCT01291537 ↗ |
| Known as | L-DOPA | “Those assigned to L-DOPA will begin taking 37.5mg carbidopa/150 mg levodopa once daily (with placebo twice daily) for one week, then increase to 75mg carbidopa/300mg levodopa...” NCT03761030 ↗5“The drug Levodopa (L-DOPA), which can replace missing dopamine in the brain, has been used to treat to treat Parkinson's disease for many decades, and it might also affect...” NCT06626152 ↗ “Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.” NCT02633839 ↗ “The purpose of this study is to investigate a new use for a medication called levodopa (L-DOPA).” NCT02560389 ↗ “Trial of L-DOPA as a Treatment to Improve Vision in Albinism” NCT01176435 ↗ “CVT-301 levodopa (l-dopa)” NCT02807675 ↗ |
| Known as | Levodopa Cyclops | “PureIMS is developing a drug-device combination product called Levodopa Cyclops®, a pre-filled drug-device combination of levodopa inhalation powder for use with the Cyclops®...” NCT06037590 ↗ |
| Known as | LIP | “CVT-301, levodopa inhalation powder (LIP)” NCT02807675 ↗ |
| Known as | melevodopa/carbidopa | “the effervescent tablet of melevodopa/carbidopa (V1512; Sirio) compared with standard-release” PMID 26171276 ↗ Jun 2015 |
| Known as | Sinemet | “levodopa (Sinemet)” NCT00006337 ↗ |
| Known as | Sirio | “the effervescent tablet of melevodopa/carbidopa (V1512; Sirio) compared with standard-release” PMID 26171276 ↗ Jun 2015 |
| Known as | V1512 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00491998 ↗ |
| Action | Activate | “L-DOPA was the natural ligand or stimulator of GPR143” NCT02873351 ↗ |
| Route | Intravenous | “Patients will stop taking their usual oral levodopa medicine and instead will have levodopa infused through a vein for up to 12 hours” NCT00006077 ↗ |
| Route | Oral | “Patients will stop taking their usual oral levodopa medicine and instead will have levodopa infused through a vein for up to 12 hours” NCT00006077 ↗ |
| Target | GPR143 | “L-DOPA binds to GPR143 in the retinal pigment epithelium” NCT02873351 ↗ |